Cargando…
Publisher Correction: Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
Autores principales: | Santano, Rebeca, Barrios, Diana, Crispi, Fàtima, Crovetto, Francesca, Vidal, Marta, Chi, Jordi, Izquierdo, Luis, Gratacós, Eduard, Moncunill, Gemma, Dobaño, Carlota |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490836/ https://www.ncbi.nlm.nih.gov/pubmed/34611293 http://dx.doi.org/10.1038/s41598-021-99604-2 |
Ejemplares similares
-
Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
por: Santano, Rebeca, et al.
Publicado: (2021) -
Making sense of emerging evidence on the non-specific effects of the BCG vaccine on malaria risk and neonatal mortality
por: Bassat, Quique, et al.
Publicado: (2020) -
RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers
por: Aguilar, Ruth, et al.
Publicado: (2023) -
Publisher Correction: An ultrasensitive planar array p24 Gag ELISA to detect HIV-1 in diverse biological matrixes
por: Levinger, Callie, et al.
Publicado: (2021) -
Performance of Multiplex Commercial Kits to Quantify Cytokine and Chemokine Responses in Culture Supernatants from Plasmodium falciparum Stimulations
por: Moncunill, Gemma, et al.
Publicado: (2013)